Neurogene (NGNE) 10-Q2023 Q1 Quarterly report

Filed: 8 May 23, 4:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: arrangement, ASC, ASH, attrition, baby, California, computationally, conservation, conserve, consummate, consummated, consummation, counterparty, Deposit, direction, disposal, disposition, dissolution, dissolve, divestiture, equal, exit, FDIC, float, headcount, hypothetical, immaterial, instability, leadership, lifted, light, magnified, maximize, minimal, morale, obsolescence, orderly, ourcertificate, passage, point, proportion, reallocation, recoverability, recoverable, reorganization, resumption, Silicon, Society, sublease, sublessee, SVB, thousand, Trust, turmoil, undertaken, undiscounted, unintended, upcoming, Valley, wrongdoing

Removed: accounted, actively, adhering, adjust, affinity, afflicted, allogeneic, Apollo, bind, biochemical, body, cancellation, CDC, cellular, chemical, complying, confirmed, conformational, contact, continuity, cultivated, degradation, Delta, depreciation, distancing, duration, eliminating, endothelial, engineering, exacerbate, expressing, extensively, frequent, functional, geographic, heterotrimeric, home, homology, hybrid, immunogenicity, immunologic, ineffective, inflamed, interact, intermolecular, invasion, killer, leak, low, mechanism, merged, mitigated, modifiable, modification, modify, modifying, monitor, monotherapy, mount, necessitate, NK, Omicron, optimize, pharmacokinetic, pharmacological, plant, posed, preferential, Prevention, priority, proteolytic, recombinant, removed, renamed, reopened, represent, resistance, resurgence, returning, scheduled, sequence, social, sponsor, spread, stable, storm, subsequently, subsidiary, succeed, surviving, therefrom, thermodynamic, tissue, top, toxicity, traded, transit, transplanted, treat, tumor, understood, unmet, unprecedented, unsafe, unviable, vascular, worsen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NGNE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

NEOLEUKIN THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Neoleukin Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Donna M. Cochener, Interim Chief Executive Officer of the Company, and Sean Smith, Interim Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of May 8, 2023.



/s/ Donna M. Cochener						/s/ Sean Smith
Donna M. Cochener						Sean Smith
Interim Chief Executive Officer						Interim Chief Financial Officer
(Principal Executive Officer)						(Principal Financial Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.